Kelly MacDonald Biography and Net Worth

Sr. VP & CFO of Dynavax Technologies

Kelly MacDonald is the Sr. VP & CFO at Dynavax Technologies.

How old is Kelly MacDonald?: Ms. MacDonald is currently 40 years old. There are 5 older executives and no younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies is Dr. Robert Janssen M.D., Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs, who is 70 years old. Learn More on Kelly MacDonald's age.
How do I contact Kelly MacDonald?: The corporate mailing address for Ms. MacDonald and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on Kelly MacDonald's contact information.
Has Kelly MacDonald been buying or selling shares of Dynavax Technologies?: Kelly MacDonald has not been actively trading shares of Dynavax Technologies during the past quarter. Learn More on Kelly MacDonald's trading history.
Who are Dynavax Technologies' active insiders?: Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.
Are insiders buying or selling shares of Dynavax Technologies?: In the last year, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 54,641 shares worth more than $729,199.23. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.
Information on this page was last updated on 5/31/2024.

Kelly MacDonald Insider Trading History at Dynavax Technologies

Kelly MacDonald Buying and Selling Activity at Dynavax Technologies

Dynavax Technologies Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Today's Range

Now: $12.42

$12.32

$12.58

50 Day Range

MA: $11.50

$10.28

$13.66

2 Week Range

Now: $12.42

$9.74

$15.01

Volume

902,686 shs

Average Volume

3,032,243 shs

Market Capitalization

$1.63 billion

P/E Ratio

95.55

Dividend Yield

N/A

Beta

1.34

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!